PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 128 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2020. The put-call ratio across all filers is 1.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $23,250 | -83.6% | 2,392 | -82.7% | 0.00% | -100.0% |
| Q4 2020 | $141,496 | +1.7% | 13,791 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $139,151 | -3.3% | 13,791 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $143,840 | +23.6% | 13,791 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $116,396 | -3.5% | 13,791 | 0.0% | 0.00% | +100.0% |
| Q4 2019 | $120,671 | -18.7% | 13,791 | 0.0% | 0.00% | -50.0% |
| Q3 2019 | $148,460 | -15.3% | 13,791 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $175,284 | -67.2% | 13,791 | 0.0% | 0.00% | -66.7% |
| Q1 2019 | $534,953 | +90.6% | 13,791 | 0.0% | 0.01% | +50.0% |
| Q4 2018 | $280,647 | -55.6% | 13,791 | 0.0% | 0.00% | -42.9% |
| Q3 2018 | $632,317 | -22.5% | 13,791 | 0.0% | 0.01% | -30.0% |
| Q2 2018 | $816,000 | -13.0% | 13,791 | 0.0% | 0.01% | -9.1% |
| Q1 2018 | $938,000 | -31.2% | 13,791 | 0.0% | 0.01% | -26.7% |
| Q4 2017 | $1,363,000 | – | 13,791 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 1,417,000 | $18,010,000 | 2.24% |
| Palo Alto Investors LP | 1,405,680 | $17,866,000 | 0.87% |
| PFM Health Sciences, LP | 2,838,376 | $36,076,000 | 0.68% |
| TANG CAPITAL MANAGEMENT LLC | 349,400 | $4,441,000 | 0.60% |
| Capital Impact Advisors, LLC | 127,029 | $1,615,000 | 0.59% |
| Leap Investments LP | 29,100 | $370,000 | 0.50% |
| Spark Investment Management LLC | 454,300 | $5,774,000 | 0.40% |
| Partner Investment Management, L.P. | 27,567 | $350,000 | 0.37% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 262,945 | $3,342,000 | 0.26% |
| Rock Springs Capital Management LP | 534,400 | $6,792,000 | 0.25% |